Paul M Tulkens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5803907/publications.pdf

Version: 2024-02-01

197 papers	14,227 citations	23567 58 h-index	22166 113 g-index
199 all docs	199 docs citations	199 times ranked	13712 citing authors

#	Article	IF	Citations
1	Lysosomotropic agents. Biochemical Pharmacology, 1974, 23, 2495-2531.	4.4	1,870
2	Tackling antibiotic resistance. Nature Reviews Microbiology, 2011, 9, 894-896.	28.6	919
3	Aminoglycosides: Activity and Resistance. Antimicrobial Agents and Chemotherapy, 1999, 43, 727-737.	3.2	762
4	Aminoglycosides: Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 1999, 43, 1003-1012.	3.2	686
5	Tissue concentrations: do we ever learn?. Journal of Antimicrobial Chemotherapy, 2007, 61, 235-237.	3.0	333
6	Antibiotic efflux pumps. Biochemical Pharmacology, 2000, 60, 457-470.	4.4	327
7	Effect of a Collaborative Approach on the Quality of Prescribing for Geriatric Inpatients: A Randomized, Controlled Trial. Journal of the American Geriatrics Society, 2007, 55, 658-665.	2.6	262
8	Mechanism of aminoglycoside-induced lysosomal phospholipidosis: In vitro and in vivo studies with Gentamicin and Amikacin. Biochemical Pharmacology, 1982, 31, 3861-3870.	4.4	228
9	Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages. Antimicrobial Agents and Chemotherapy, 2006, 50, 841-851.	3.2	228
10	Glycopeptide Antibiotics. Drugs, 2004, 64, 913-936.	10.9	181
11	Comparative Stability Studies of Antipseudomonal Î²-Lactams for Potential Administration through Portable Elastomeric Pumps (Home Therapy for Cystic Fibrosis Patients) and Motor-Operated Syringes (Intensive Care Units). Antimicrobial Agents and Chemotherapy, 2002, 46, 2327-2332.	3.2	178
12	Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney International, 1984, 25, 643-652.	5.2	167
13	Intracellular pharmacodynamics of antibiotics. Infectious Disease Clinics of North America, 2003, 17, 615-634.	5.1	164
14	Aminoglycoside-induced renal phospholipidosis and nephrotoxicity. Biochemical Pharmacology, 1990, 40, 2383-2392.	4.4	161
15	Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin againstStaphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2011, 55, 649-658.	3.2	160
16	The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochemical Pharmacology, 1978, 27, 415-424.	4.4	155
17	Hepatic safety of antibiotics used in primary care. Journal of Antimicrobial Chemotherapy, 2011, 66, 1431-1446.	3.0	154
18	Antibiotic activity against small-colony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. Journal of Antimicrobial Chemotherapy, 2013, 68, 1455-1464.	3.0	154

#	Article	IF	Citations
19	Fate of plasma membrane during endocytosis. II. Evidence for recycling (shuttle) of plasma membrane constituents. Journal of Cell Biology, 1979, 82, 466-474.	5.2	143
20	ANALYTICAL FRACTIONATION OF HOMOGENATES FROM CULTURED RAT EMBRYO FIBROBLASTS. Journal of Cell Biology, 1974, 63, 383-401.	5.2	142
21	Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 Macrophages. Antimicrobial Agents and Chemotherapy, 2003, 47, 2283-2292.	3.2	140
22	The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends in Pharmacological Sciences, 2008, 29, 124-134.	8.7	129
23	Gentamicin-induced apoptosis in LLC-PK1 cells: Involvement of lysosomes and mitochondria. Toxicology and Applied Pharmacology, 2005, 206, 321-333.	2.8	124
24	Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. Journal of Antimicrobial Chemotherapy, 1987, 20, 47-56.	3.0	121
25	Apoptosis in Renal Proximal Tubules of Rats Treated with Low Doses of Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2000, 44, 665-675.	3.2	116
26	Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of Î²-Lactams, Azithromycin, Gentamicin, and Fluoroquinolones against Listeria monocytogenes at Clinically Relevant Concentrations. Antimicrobial Agents and Chemotherapy, 2002, 46, 2095-2103.	3.2	116
27	A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 2726-2737.	3.2	114
28	Safety Profile of the Respiratory Fluoroquinolone Moxifloxacin. Drug Safety, 2009, 32, 359-378.	3.2	108
29	Temocillin revived. Journal of Antimicrobial Chemotherapy, 2008, 63, 243-245.	3.0	107
30	Multidrug-Resistant Streptococcus pneumoniae Infections. Drugs, 2007, 67, 2355-2382.	10.9	104
31	Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2003, 51, 1167-1173.	3.0	101
32	Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2006, 58, 1177-1184.	3.0	100
33	Stability of meropenem and doripenem solutions for administration by continuous infusion. Journal of Antimicrobial Chemotherapy, 2010, 65, 1073-1075.	3.0	100
34	Experimental studies on nephrotoxicity of aminoglycosides at low doses: Mechanisms and perspectives. American Journal of Medicine, 1986, 80, 105-114.	1.5	94
35	Role of oxidative stress in lysosomal membrane permeabilization and apoptosis induced by gentamicin, an aminoglycoside antibiotic. Free Radical Biology and Medicine, 2011, 51, 1656-1665.	2.9	91
36	Increased Susceptibility of Pseudomonas aeruginosa to Macrolides and Ketolides in Eukaryotic Cell Culture Media and Biological Fluids Due to Decreased Expression of oprM and Increased Outer-Membrane Permeability. Clinical Infectious Diseases, 2012, 55, 534-542.	5.8	90

#	Article	IF	Citations
37	Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 6385-6397.	3.2	88
38	Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. Journal of Antimicrobial Chemotherapy, 2006, 59, 246-253.	3.0	87
39	Implementation of Ward-Based Clinical Pharmacy Services in Belgiumâ€"Description of the Impact on a Geriatric Unit. Annals of Pharmacotherapy, 2006, 40, 720-728.	1.9	85
40	Appropriateness of use of medicines in elderly inpatients: qualitative study. BMJ: British Medical Journal, 2005, 331, 935.	2.3	81
41	A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2007, 59, 378-386.	3.0	78
42	Interactions of ciprofloxacin with DPPC and DPPG: Fluorescence anisotropy, ATR-FTIR and 31P NMR spectroscopies and conformational analysis. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 2535-2543.	2.6	78
43	Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. Journal of Antimicrobial Chemotherapy, 2008, 61, 382-388.	3.0	78
44	Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 1832-1840.	2.6	77
45	Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function. Antimicrobial Agents and Chemotherapy, 2015, 59, 178-185.	3.2	77
46	Optimizing Î²-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?. Expert Review of Anti-Infective Therapy, 2017, 15, 677-688.	4.4	77
47	Azithromycin, a Lysosomotropic Antibiotic, Has Distinct Effects on Fluid-Phase and Receptor-Mediated Endocytosis, but Does Not Impair Phagocytosis in J774 Macrophages. Experimental Cell Research, 2002, 281, 86-100.	2.6	76
48	Influence of Efflux Transporters on the Accumulation and Efflux of Four Quinolones (Ciprofloxacin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Chemotherapy, 2005, 49, 2429-2437.	3.2	76
49	Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK 1 Cells Subjected to Electroporation. Antimicrobial Agents and Chemotherapy, 2006, 50, 1213-1221.	3.2	73
50	Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils. Antimicrobial Agents and Chemotherapy, 2010, 54, 2540-2548.	3.2	73
51	In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. International Journal of Antimicrobial Agents, 2010, 36, 513-522.	2.5	72
52	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. Journal of Antimicrobial Chemotherapy, 2015, 70, 891-898.	3.0	71
53	Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse Macrophages. Antimicrobial Agents and Chemotherapy, 2004, 48, 2853-2860.	3.2	66
54	Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochemical Pharmacology, 1988, 37, 591-599.	4.4	65

#	Article	IF	Citations
55	Influence of P-Glycoprotein Inhibitors on Accumulationof Macrolides in J774 MurineMacrophages. Antimicrobial Agents and Chemotherapy, 2003, 47, 1047-1051.	3.2	64
56	Molecular models of human P-glycoprotein in two different catalytic states. BMC Structural Biology, 2009, 9, 3.	2.3	63
57	Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. Journal of Antimicrobial Chemotherapy, 2003, 51, 651-658.	3.0	60
58	Mechanism of the Intracellular Killing and Modulation of Antibiotic Susceptibility ofListeria monocytogenesin THP-1 Macrophages Activated by Gamma Interferon. Antimicrobial Agents and Chemotherapy, 1999, 43, 1242-1251.	3.2	59
59	Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. Journal of Antimicrobial Chemotherapy, 2009, 64, 1035-1043.	3.0	59
60	Plectasin Shows Intracellular Activity against Staphylococcus aureus in Human THP-1 Monocytes and in a Mouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 4801-4808.	3.2	59
61	Cellular Pharmacodynamics of the Novel Biaryloxazolidinone Radezolid: Studies with Infected Phagocytic and Nonphagocytic cells, UsingStaphylococcus aureus,Staphylococcus epidermidis,Listeria monocytogenes, andLegionella pneumophila. Antimicrobial Agents and Chemotherapy, 2010, 54, 2549-2559.	3.2	58
62	Stability and Compatibility of Ceftazidime Administered by Continuous Infusion to Intensive Care Patients. Antimicrobial Agents and Chemotherapy, 2001, 45, 2643-2647.	3.2	55
63	Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. International Journal of Antimicrobial Agents, 2009, 34, 555-560.	2.5	55
64	High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. International Journal of Antimicrobial Agents, 2016, 48, 740-743.	2.5	55
65	Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Current Opinion in Drug Discovery & Development, 2006, 9, 218-30.	1.9	55
66	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains. Antimicrobial Agents and Chemotherapy, 2009, 53, 1434-1442.	3.2	54
67	Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. European Journal of Pharmacology, 1996, 314, 203-214.	3.5	53
68	Modulation of the Cellular Accumulation and Intracellular Activity of Daptomycin towards Phagocytized Staphylococcus aureus by the P-Glycoprotein (MDR1) Efflux Transporter in Human THP-1 Macrophages and Madin-Darby Canine Kidney Cells. Antimicrobial Agents and Chemotherapy, 2007, 51, 2748-2757.	3.2	53
69	Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, againstStaphylococcus aureus,Listeria monocytogenes, andLegionella pneumophilain Human THP-1 Macrophages. Antimicrobial Agents and Chemotherapy, 2009, 53, 3734-3743.	3.2	53
70	Active Efflux of Ciprofloxacin from J774 Macrophages through an MRP-Like Transporter. Antimicrobial Agents and Chemotherapy, 2004, 48, 2673-2682.	3.2	52
71	Water-soluble amphotericin Bâ€“polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. Journal of Antimicrobial Chemotherapy, 2006, 57, 236-244.	3.0	52
72	Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. International Journal of Antimicrobial Agents, 2011, 38, 52-59.	2.5	52

#	Article	IF	Citations
73	Activity of three Î²-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2005, 55, 897-904.	3.0	50
74	Fluoroquinolones induce the expression of patA and patB, which encode ABC efflux pumps in Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy, 2010, 65, 2076-2082.	3.0	50
75	Stability and compatibility of vancomycin for administration by continuous infusion. Journal of Antimicrobial Chemotherapy, 2013, 68, 1179-1182.	3.0	50
76	Pharmacodynamic Evaluation of the Intracellular Activity of Antibiotics towards Pseudomonas aeruginosa PAO1 in a Model of THP-1 Human Monocytes. Antimicrobial Agents and Chemotherapy, 2013, 57, 2310-2318.	3.2	49
77	Ultrastructural, physico-chemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether)hexestrol with negatively-charged phospholipid layers. Biochemical Pharmacology, 1989, 38, 729-741.	4.4	47
78	Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis. International Journal of Antimicrobial Agents, 2018, 52, 697-701.	2.5	47
79	Moxifloxacin Safety. Drugs in R and D, 2012, 12, 71-100.	2.2	45
80	Alterations in membrane permeability induced by aminoglycoside antibiotics: studies on liposomes and cultured cells. European Journal of Pharmacology, 1993, 247, 155-168.	2.6	44
81	Profile of a Novel Anionic Fluoroquinoloneâ€"Delafloxacin. Clinical Infectious Diseases, 2019, 68, S213-S222.	5.8	44
82	Association Between Antibiotic Sales and Public Campaigns for Their Appropriate Use. JAMA - Journal of the American Medical Association, 2004, 292, 2465.	7.4	43
83	Dynamics and Structural Changes Induced by ATP Binding in SAV1866, a Bacterial ABC Exporter. Journal of Physical Chemistry B, 2010, 114, 15948-15957.	2.6	43
84	Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe. Antimicrobial Agents and Chemotherapy, 2016, 60, 6735-6741.	3.2	43
85	Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations. Journal of Antimicrobial Chemotherapy, 2007, 60, 965-972.	3.0	42
86	Acquired resistance to macrolides inPseudomonas aeruginosafrom cystic fibrosis patients. European Respiratory Journal, 2017, 49, 1601847.	6.7	42
87	Restoration of Susceptibility of Methicillin-resistant Staphylococcus aureus to Î²-Lactam Antibiotics by Acidic pH. Journal of Biological Chemistry, 2008, 283, 12769-12776.	3.4	41
88	Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Methicillin-ResistantStaphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2009, 53, 2289-2297.	3.2	41
89	Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. Journal of Antimicrobial Chemotherapy, 2010, 65, 1720-1724.	3.0	41
90	Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. Annals of Intensive Care, 2012, 2, 22.	4.6	41

#	Article	IF	Citations
91	The antifungal caspofungin increases fluoroquinolone activity against Staphylococcus aureus biofilms by inhibiting N-acetylglucosamine transferase. Nature Communications, 2016, 7, 13286.	12.8	41
92	Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. Journal of Antimicrobial Chemotherapy, 2003, 51, 1051-1052.	3.0	40
93	Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. International Journal of Antimicrobial Agents, 2013, 41, 439-446.	2.5	40
94	Role ofrsbUand Staphyloxanthin in Phagocytosis and Intracellular Growth ofStaphylococcus aureusin Human Macrophages and Endothelial Cells. Journal of Infectious Diseases, 2009, 200, 1367-1370.	4.0	39
95	Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides, 2012, 35, 248-252.	2.4	39
96	Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 267-283.	1.8	37
97	Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Study of Antibiotic Combinations. Antimicrobial Agents and Chemotherapy, 2009, 53, 1443-1449.	3.2	37
98	Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. Laboratory Investigation, 1979, 40, 481-91.	3.7	37
99	Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Safety Summary. Clinical Infectious Diseases, 2014, 58, S51-S57.	5.8	36
100	Immunological Inhibition of Lysosome Function. Nature, 1970, 228, 1282-1285.	27.8	35
101	Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibioticsâ€"I. Biochemical Pharmacology, 1990, 40, 489-497.	4.4	35
102	Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. European Journal of Pharmacology, 1996, 314, 215-227.	3.5	35
103	Azithromycin, a lysosomotropic antibiotic, impairs fluid-phase pinocytosis in cultured fibroblasts. European Journal of Cell Biology, 2001, 80, 466-478.	3.6	35
104	Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages. International Journal of Antimicrobial Agents, 2011, 38, 249-56.	2.5	34
105	Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic. Scientific Reports, 2017, 7, 40208.	3.3	34
106	Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	33
107	Mixed-Lipid Storage Disorder Induced in Macrophages and Fibroblasts by Oritavancin (LY333328), a New Glycopeptide Antibiotic with Exceptional Cellular Accumulation. Antimicrobial Agents and Chemotherapy, 2005, 49, 1695-1700.	3.2	32
108	Role of Acidic pH in the Susceptibility of Intraphagocytic Methicillin-Resistant Staphylococcus aureus Strains to Meropenem and Cloxacillin. Antimicrobial Agents and Chemotherapy, 2007, 51, 1627-1632.	3.2	32

#	Article	IF	Citations
109	Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. Journal of Antimicrobial Chemotherapy, 2011, 66, 596-607.	3.0	32
110	Activity of Fusidic Acid Against Extracellular and Intracellular Staphylococcus aureus: Influence of pH and Comparison With Linezolid and Clindamycin. Clinical Infectious Diseases, 2011, 52, S493-S503.	5.8	31
111	Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic) Tj ETQq1 1 0.784314 rgBT /Overlock 10	3.0	30
112	Mechanisms of Action. , 2017, , 1162-1180.e1.		30
113	Impairment of Growth ofListeria monocytogenesin THPâ€1 Macrophages by Granulocyte Macrophage Colonyâ€Stimulating Factor: Release of Tumor Necrosis Factorâ€“Î± and Nitric Oxide. Journal of Infectious Diseases, 2004, 189, 2101-2109.	4.0	29
114	Predicting the three-dimensional structure of human P-glycoprotein in absence of ATP by computational techniques embodying crosslinking data: Insight into the mechanism of ligand migration and binding sites. Proteins: Structure, Function and Bioinformatics, 2006, 63, 466-478.	2.6	28
115	Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1596-1598.	3.0	27
116	Cooperation between Prokaryotic (Lde) and Eukaryotic (MRP) Efflux Transporters in J774 Macrophages Infected withListeria monocytogenes: Studies with Ciprofloxacin and Moxifloxacin. Antimicrobial Agents and Chemotherapy, 2008, 52, 3040-3046.	3.2	26
117	Restoration of Susceptibility of Intracellular Methicillin-ResistantStaphylococcus aureusto Î²-Lactams: Comparison of Strains, Cells, and Antibiotics. Antimicrobial Agents and Chemotherapy, 2008, 52, 2797-2805.	3.2	26
118	Identification of the Efflux Transporter of the Fluoroquinolone Antibiotic Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells. Antimicrobial Agents and Chemotherapy, 2009, 53, 2410-2416.	3.2	26
119	Inhibition of the Injectisome and Flagellar Type III Secretion Systems by INP1855 ImpairsPseudomonas aeruginosaPathogenicity and Inflammasome Activation. Journal of Infectious Diseases, 2016, 214, 1105-1116.	4.0	26
120	Cellular Accumulation and Activity of Quinolones in Ciprofloxacin-Resistant J774 Macrophages. Antimicrobial Agents and Chemotherapy, 2006, 50, 1689-1695.	3.2	24
121	Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. Journal of Antimicrobial Chemotherapy, 2010, 65, 962-973.	3.0	24
122	Comparative toxicity of aminoglycoside antibiotics towards the lysosomes in a cell culture model. Toxicology, 1980, 17, 195-199.	4.2	21
123	Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. Chemistry and Physics of Lipids, 2005, 133, 1-15.	3.2	21
124	Intra- and Extracellular Activities of Dicloxacillin against Staphylococcus aureus In Vivo and In Vitro. Antimicrobial Agents and Chemotherapy, 2010, 54, 2391-2400.	3.2	21
125	Macrophage Killing of Bacterial and Fungal Pathogens Is Not Inhibited by Intense Intracellular Accumulation of the Lipoglycopeptide Antibiotic Oritavancin. Clinical Infectious Diseases, 2012, 54, S229-S232.	5.8	21
126	Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Cultured Human HL-60 Promyelocytes and THP-1 Monocytes. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	21

#	Article	IF	Citations
127	Pharmacological Characterization of 7-(4-(Piperazin-1-yl)) Ciprofloxacin Derivatives: Antibacterial Activity, Cellular Accumulation, Susceptibility to Efflux Transporters, and Intracellular Activity. Pharmaceutical Research, 2014, 31, 1290-1301.	3.5	20
128	Increase of efflux-mediated resistance in Pseudomonas aeruginosa during antibiotic treatment in patients suffering from nosocomial pneumonia. International Journal of Antimicrobial Agents, 2016, 47, 77-83.	2.5	20
129	Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers. Antibiotics, 2021, 10, 530.	3.7	20
130	Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. FEBS Letters, 1996, 394, 307-310.	2.8	19
131	Accumulation and Oriented Transport of Ampicillin in Caco-2 Cells from Its Pivaloyloxymethylester Prodrug, Pivampicillin. Antimicrobial Agents and Chemotherapy, 2005, 49, 1279-1288.	3.2	19
132	Intra- and Extracellular Activities of Dicloxacillin and Linezolid against a ClinicalStaphylococcus aureusStrain with a Small-Colony-Variant Phenotype in anIn VitroModel of THP-1 Macrophages and anIn VivoMouse Peritonitis Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 1443-1452.	3.2	19
133	Study of Macrophage Functions in Murine J774 Cells and Human Activated THP-1 Cells Exposed to Oritavancin, a Lipoglycopeptide with High Cellular Accumulation. Antimicrobial Agents and Chemotherapy, 2014, 58, 2059-2066.	3.2	19
134	Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
135	Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes. Journal of Antimicrobial Chemotherapy, 2008, 62, 518-521.	3.0	18
136	Isolation and 2â€Dâ€DIGE proteomic analysis of intracellular and extracellular forms of Listeria monocytogenes. Proteomics, 2009, 9, 5484-5496.	2.2	18
137	Antibiotic Activity against Naive and Induced Streptococcus pneumoniae Biofilms in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 1348-1358.	3.2	18
138	Modulation of Intracellular Growth ofListeria monocytogenesin Human Enterocyte Cacoâ€2 Cells by Interferonâ€Î³ and Interleukinâ€6: Role of Nitric Oxide and Cooperation with Antibiotics. Journal of Infectious Diseases, 1999, 180, 1195-1204.	4.0	17
139	Cocaine induces a mixed lysosomal lipidosis in cultured fibroblasts, by inactivation of acid sphingomyelinase and inhibition of phospholipase A1. Toxicology and Applied Pharmacology, 2004, 194, 101-110.	2.8	17
140	Activities of Antibiotic Combinations against Resistant Strains of Pseudomonas aeruginosa in a Model of Infected THP-1 Monocytes. Antimicrobial Agents and Chemotherapy, 2015, 59, 258-268.	3.2	17
141	The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2016, 14, 311-324.	4.4	17
142	Apoptosis Induced by Aminoglycosides in LLC-PK1 Cells: Comparative Study of Neomycin, Gentamicin, Amikacin, and Isepamicin Using Electroporation. Antimicrobial Agents and Chemotherapy, 2008, 52, 2236-2238.	3.2	16
143	Role of MexAB-OprM in intrinsic resistance of Pseudomonas aeruginosa to temocillin and impact on the susceptibility of strains isolated from patients suffering from cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2012, 67, 771-775.	3.0	16
144	Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin. Journal of Antimicrobial Chemotherapy, 2013, 68, 648-658.	3.0	16

#	Article	IF	Citations
145	Correlation between cytotoxicity induced byPseudomonas aeruginosaclinical isolates from acute infections and IL-1Î² secretion in a model of human THP-1 monocytes. Pathogens and Disease, 2015, 73, ftv049.	2.0	16
146	Cellular Pharmacokinetics and Intracellular Activity of the Novel Peptide Deformylase Inhibitor GSK1322322 against Staphylococcus aureus Laboratory and Clinical Strains with Various Resistance Phenotypes: Studies with Human THP-1 Monocytes and J774 Murine Macrophages. Antimicrobial Agents and Chemotherapy, 2015, 59, 5747-5760.	3.2	16
147	Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes. International Journal of Antimicrobial Agents, 2019, 54, 702-708.	2.5	16
148	Antibiotic Resistance, Biofilm Formation, and Intracellular Survival As Possible Determinants of Persistent or Recurrent Infections by Staphylococcus aureus in a Vietnamese Tertiary Hospital: Focus on Bacterial Response to Moxifloxacin. Microbial Drug Resistance, 2020, 26, 537-544.	2.0	16
149	Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. Pharmaceutical Research, 2003, 20, 624-631.	3.5	15
150	Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. Journal of Antimicrobial Chemotherapy, 2010, 65, 1228-1236.	3.0	15
151	Long-term stability of temocillin in elastomeric pumps for outpatient antibiotic therapy in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 2045-2046.	3.0	15
152	Intracellular forms of menadione-dependent small-colony variants of methicillin-resistant Staphylococcus aureus are hypersusceptible to Â-lactams in a THP-1 cell model due to cooperation between vacuolar acidic pH and oxidant species. Journal of Antimicrobial Chemotherapy, 2012, 67, 2873-2881.	3.0	15
153	Subcellular mechanisms involved in apoptosis induced by aminoglycoside antibiotics: Insights on p53, proteasome and endoplasmic reticulum. Toxicology and Applied Pharmacology, 2016, 309, 24-36.	2.8	15
154	Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. Biochemical Pharmacology, 1992, 43, 895-898.	4.4	14
155	Leupeptin and E-64, inhibitors of cysteine proteinases, prevent gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Toxicology Letters, 1994, 73, 201-208.	0.8	14
156	Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	14
157	Syntheses and hydrolysis of basic and dibasic ampicillin esters tailored for intracellular accumulation. Bioorganic and Medicinal Chemistry, 2001, 9, 493-502.	3.0	13
158	Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of Staphylococcus aureus and Their Wild-Type Parental Strain in Human THP-1 Cells. Antimicrobial Agents and Chemotherapy, 2012, 56, 6166-6174.	3.2	13
159	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. Clinical Biochemistry, 2015, 48, 542-545.	1.9	12
160	Modulating antibiotic activity towards respiratory bacterial pathogens by co-medications: a multi-target approach. Drug Discovery Today, 2016, 21, 1114-1129.	6.4	12
161	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. Methods in Molecular Biology, 2016, 1333, 147-157.	0.9	12
162	Characterization of Abcc4 Gene Amplification in Stepwise-Selected Mouse J774 Macrophages Resistant to the Topoisomerase II Inhibitor Ciprofloxacin. PLoS ONE, 2011, 6, e28368.	2.5	12

#	Article	IF	Citations
163	Development and validation of a high performance liquid chromatography assay for the determination of temocillin in serum of haemodialysis patients. Journal of Pharmaceutical and Biomedical Analysis, 2014, 90, 192-197.	2.8	11
164	The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin. Frontiers in Microbiology, 2020, 11, 587364.	3.5	11
165	Molecular Analysis of Rising Fluoroquinolone Resistance in Belgian Non-Invasive Streptococcus pneumoniae Isolates (1995-2014). PLoS ONE, 2016, 11, e0154816.	2.5	11
166	Penicillin-binding Proteins (PBP) and Lmo0441 (a PBP-like protein) play a role in Beta-lactam sensitivity of Listeria monocytogenes. Gut Pathogens, 2009, 1, 23.	3.4	10
167	Characterisation of a collection of Streptococcus pneumoniae isolates from patients suffering from acute exacerbations of chronic bronchitis: In vitro susceptibility to antibiotics and biofilm formation in relation to antibiotic efflux and serotypes/serogroups. International Journal of Antimicrobial Agents, 2014, 44, 209-217.	2.5	10
168	Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin. Toxicology, 2011, 290, 178-186.	4.2	9
169	Development of clinical pharmacy in Belgian hospitals through pilot projects funded by the government. Acta Clinica Belgica, 2019, 74, 75-81.	1.2	9
170	Content Validity and Inter-Rater Reliability of an Instrument to Characterize Unintentional Medication Discrepancies. Drugs and Aging, 2012, 29, 577-591.	2.7	9
171	Adverse Drug Reactions to Antiretroviral Therapy: Prospective Study in Children in Sikasso (Mali). Journal of Pediatric Pharmacology and Therapeutics, 2012, 17, 382-388.	0.5	9
172	Intracellular accumulation and activity of ampicillin used as freedrug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against Listeria monocytogenes in J774 macrophages. Journal of Antimicrobial Chemotherapy, 2003, 52, 610-615.	3.0	8
173	Antimicrobial susceptibility of Streptococcus pneumoniae isolates from vaccinated and non-vaccinated patients with a clinically confirmed diagnosis of community-acquired pneumonia in Belgium. International Journal of Antimicrobial Agents, 2012, 39, 208-216.	2.5	8
174	Analysis of the Membrane Proteome of Ciprofloxacin-Resistant Macrophages by Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC). PLoS ONE, 2013, 8, e58285.	2.5	8
175	Long-term stability of temocillin in dextrose 5% and in sodium chloride 0.9% polyolefin bags at 5Â±3Â°C after freeze-thaw treatment. Annales Pharmaceutiques Francaises, 2011, 69, 296-301.	1.0	7
176	Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. International Journal of Antimicrobial Agents, 2020, 55, 105825.	2.5	7
177	Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in anIn VitroModel of Intracellular Infection. Antimicrobial Agents and Chemotherapy, 2021, 65, e0146821.	3.2	7
178	The Putative De-N-acetylase DnpA Contributes to Intracellular and Biofilm-Associated Persistence of Pseudomonas aeruginosa Exposed to Fluoroquinolones. Frontiers in Microbiology, 2018, 9, 1455.	3.5	6
179	Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells. International Journal of Antimicrobial Agents, 2020, 55, 105848.	2.5	6
180	Thrice-weekly temocillin administered after each dialysis session is appropriate for the treatment of serious Gram-negative infections in haemodialysis patients. International Journal of Antimicrobial Agents, 2015, 46, 660-665.	2.5	5

#	Article	IF	Citations
181	Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience. International Journal of Basic and Clinical Pharmacology, 2019, 8, 831.	0.1	5
182	Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of Staphylococcus aureus Differing by Their Resistant or Persister Character to Fluoroquinolones. Frontiers in Microbiology, 2021, 12, 785573.	3.5	5
183	Design and evaluation of analogues of the bacterial cell-wall peptidoglycan motif l-Lys-d-Ala-d-Ala for use in a vancomycin biosensor. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5758-5762.	2.2	4
184	Modulation of the activity of moxifloxacin and solithromycin in an in vitro pharmacodynamic model of Streptococcus pneumoniae naive and induced biofilms. Journal of Antimicrobial Chemotherapy, 2015, 70, 1713-26.	3.0	4
185	Temocillin dosing in haemodialysis patients based on population pharmacokinetics of total and unbound concentrations and Monte Carlo simulations. Journal of Antimicrobial Chemotherapy, 2018, 73, 1630-1638.	3.0	4
186	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics, 2022, 11, 898.	3.7	4
187	Pseudomonas aeruginosa : rÃ©sistance et options thÃ©rapeutiques Ã lâ€™aube du deuxiÃ¨me millÃ©naire. Antibiotiques, 2007, 9, 189-198.	0.1	3
188	Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2011, 66, 948-951.	3.0	3
189	Editorial Commentary: Colistin and a New Paradigm in Drug Development. Clinical Infectious Diseases, 2016, 62, 559-560.	5.8	3
190	Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines. International Journal of Antimicrobial Agents, 2019, 54, 661-667.	2.5	3
191	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. Journal of Antimicrobial Chemotherapy, 2019, 74, 1459-1461.	3.0	2
192	In Vitro Models for the Study of the Intracellular Activity of Antibiotics. Methods in Molecular Biology, 2021, 2357, 239-251.	0.9	2
193	Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. Journal of Antimicrobial Chemotherapy, 2021, 76, iv9-iv22.	3.0	2
194	Inhibition of TNF-Â production in THP-1 macrophages by glatiramer acetate does not alter their susceptibility to infection by Listeria monocytogenes and does not impair the efficacy of ampicillin or moxifloxacin against intracellular bacteria. Journal of Antimicrobial Chemotherapy, 2004, 54, 288-289.	3.0	1
195	RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria. Antimicrobial Agents and Chemotherapy, 2015, 59, 4750-4758.	3.2	1
196	Phosphocholine May Allow for Listeriolysin-Mediated Escape of Phagocytized Listeria From Vacuolar Compartments Into the Host Cytosol While Protecting Against Overt Destruction of the Infected Cell. Journal of Infectious Diseases, 2020, 222, 1425-1427.	4.0	0
197	Mechanisms of action. , 2010, , 1288-1307.		0